FDA Grants Breakthrough Therapy Designation for Genentech’s Alecensa® (Alectinib) for First-Line Treatment of People with ALK-Positive NSCLC
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application for Myopic Choroidal Neovascularization
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
Maxygen MAXY announced that its partner Roche RHHBY placed a hold on development of Maxy-Alpha--the first of Maxygen's shuffled proteins to enter clinical development--and we're lowering our fair value estimate accordingly. While we had only placed a 20% probability on the eventual approval of ...
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.
Firm has a promising strategy of combining expertise in both areas to generate a growing personalized medicine pipeline.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Ariel International marks the firm’s first foray into foreign-stock investing. It has been a performance success so far.
Readers say diversification and exposure to good companies call for looking beyond the U.S.
Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.